FDA Clearance Tracker · P150046
NEVISENSE
Last checked: Nov 20, 2026Latest source record: Jun 28, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Jun 28, 2017
Approved (reclassified)
Time to decision
569 days
Received Dec 7, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P150046
- Device name
- NEVISENSE
- Applicant
- Scibase AB
- Applicant location
- Stockholm
- Received
- Dec 7, 2015
- Decided
- Jun 28, 2017
- Decision
- Approved (reclassified)
- Supplements
- 6 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Electrical Impedance Spectrometer (ONV)
- Device class
- Class II
- Regulation
- 21 CFR 878.1820
- Specialty
- General & Plastic Surgery
FDA's approval statement
As written in FDA's record.
Approval for the Nevisense. This device is indicated for use on cutaneous lesions with one or more clinical or historical characteristics of melanoma, when a dermatologist chooses to obtain additional information when considering biopsy. Nevisense should not be used on clinically obvious melanoma. The Nevisense result is one element of the overall clinical assessment. The output of Nevisense should be used in combination with clinical and historical signs of melanoma to obtain additional information prior to a decision to biopsy. Nevisense is indicated only for use on: primary skin lesions with a diameter between 2 mm and 20 mm; lesions that are accessible by the Nevisense probe; lesions where the skin is intact (i.e., non-ulcerated or non-bleeding lesions); lesions that do not contain a scar or fibrosis consistent with previous trauma; lesions not located in areas of psoriasis, eczema, acute sunburn, or similar skin conditions; lesions not in hair-covered areas; lesions which do not contain foreign matter; lesions not on special anatomic sites (i.e., not for use on acral skin, genitalia, eyes, mucosal areas).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code ONV (Electrical Impedance Spectrometer).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Scibase AB
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.